ICU Delirium | Bayesian analysis suggests high probabilities of benefits and low probabilities of harm with the use of haloperidol

Haloperidol vs. placebo for the treatment of delirium in ICU patients: a pre-planned, secondary Bayesian analysis of the AID–ICU trial – Intensive Care Medicine (free for a limited period)

Original article: RCT | Haloperidol for the treatment of delirium in ICU patients did not significantly improve outcomes.

Commentary on Twitter

Haloperidol vs placebo in acutely admitted, adult #ICU pts with #delirium? With IV haloperidol 2.5 mg × 3 daily & as needed doses up to max 20 mg daily:
➡️ high probabilities of benefits
➡️ low probabilities of harm for primary & most secondary outcomes
?️ https://t.co/iNRVVozlRJ pic.twitter.com/NJbhvxxdYx

— Intensive Care Medicine (@yourICM) March 27, 2023